Bayer’s Eylea primary endpoint in two Phase III trials for DME

27 September 2013

German pharma and chemical major Bayer (BAYN: DE) this morning said that Eylea (aflibercept solution for injection, known in the scientific literature as VEGF Trap-Eye) has achieved the primary endpoint in two pivotal phase III trials for the treatment of diabetic macular (o)edema (DME/DMO), the leading cause of sight loss in people suffering from diabetes.

These results from the Phase III trials, VIVID-DME and VISTA-DME, were presented at the13th EURETINA Congress in Hamburg, Germany. Eylea is licensed from US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK